PCA
BMRN icon

Providence Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Providence Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14
Closed -$1K – 309
2022
Q1 		$1K Buy
+14
New +$1.17K ﹤0.01% 412
2019
Q2 		– Sell
-11
Closed -$1K – 257
2019
Q1 		$1K Buy
+11
New +$1.02K ﹤0.01% 269

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Providence Capital Advisors's BMRN Position: Q2 2022 in Review

Providence Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 14 shares — an estimated $1K sold.

Providence Capital Advisors first reported a position in BMRN in Q1 2019 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

  • Providence Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 14 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • Providence Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Providence Capital Advisors's BioMarin Pharmaceuticals position peaked at $1K in Q1 2022.
  • 542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.